ABOUT
Overview
Dr. Evan Cole Lewis is a Neurologist with specialization in pediatric neurology and epilepsy. He is an Assistant Professor (Adjunct) with the Department of Pediatrics at the Hospital for Sick Children and the University of Toronto. He currently works as a consultant neurologist for both adults and children at North Toronto Neurology in Toronto, Canada. Dr. Lewis’ clinical work focuses on epilepsy; concussion & persisting symptoms after concussion; functional neurological disorder, in particular functional seizures; and cannabis and psychedelic therapies for neurologic disorders.
Dr. Lewis was the founder of the Neurology Centre of Toronto where he served as medical director from 2016 to 2024. He served as VP Psychedelic Neurology for Numinus from 2021 to 2024 and is the current Chief Medical Advisor for the Jamaican Medical Cannabis Corporation Group.
Dr. Lewis’ research interests lie in the fields of psychedelic and cannabis therapies for neurologic disorders.
Education, Training & Work
Dr. Lewis attained his MD from the University of Ottawa and trained as a Pediatric Neurologist at the Children’s Hospital of Eastern Ontario (CHEO). He completed fellowships in both clinical neurophysiology and epilepsy at Nicklaus Children’s Hospital (formerly known as Miami Children’s Hospital) and the Hospital for Sick Children. Dr. Lewis held staff positions at SickKids and Holland Bloorview Kids Rehabilitation Hospital between 2016 and 2018.
Work in Medical Cannabis
Dr. Lewis has significant clinical experience with medical cannabis in adults and children and has spoken extensively on cannabis in neurologic disorders nationally and internationally. He is a member of the Cannabinoid Research Initiative of Saskatchewan (CRIS) and the Canadian Childhood Cannabinoid Clinical Trials (C4T) group. Dr. Lewis is a co-investigator on two medical cannabis trials, one targeting chronic headaches among adolescents and the other employing cannabis to address drug-resistant epilepsy in both children and adults.
In the United Kingdom, he is a member of the Expert Committee of the Medical Cannabis Clinicians Society (MCCS) and an advisor for the Medical Cannabis Working Group for Drug Science and MedCan. He has delivered educational seminars, talks and lectures on the therapeutic use of medical cannabis in neurology both locally and internationally.
Work in Psychedelic Medicines
Dr. Lewis’ clinical and research focus in psychedelic medicine includes indications, treatment and novel approaches. He has clinical experience counselling patients with underlying neurologic conditions who have utilized psychedelics such as psilocybin, MDMA and ketamine. Dr. Lewis utilizes psychedelic-assisted therapy in adults and adolescents as adjunct treatment for functional neurological disorders, functional seizures, persisting symptoms after concussion, and co-morbid mental health conditions that arise from neurologic diagnoses. He has delivered educational seminars, talks and lectures on the intersection of psychedelics in neurology both locally and internationally.
Postions & Research
Dr. Lewis is a Fellow of the Royal College of Physicians of Canada and was the Tariff Chair of the Neurology Section for the Ontario Medical Association from 2017 - 2019. He sits on the Editorial Board for the Journal of Child Neurology’s Resident/Fellow Section and is a reviewer for the Canadian Journal of Neurological Sciences, Paediatrics & Child Health, Epilepsy & Behaviour and the NIHR in the UK. His research interests include psychedelic neurology, cannabinoids in the treatment of epilepsy & other neurological conditions and the delivery of novel virtual care models in neurology. His special clinical interests include functional neurological disorders and treatment of chronic symptoms of TBI.
Publications:
Link to Publications: https://goo.gl/yLhvN1